contrave
| Product dosage: 98mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.46 | $49.17 (0%) | 🛒 Add to cart |
| 30 | $2.34 | $73.75 $70.24 (5%) | 🛒 Add to cart |
| 60 | $2.29 | $147.50 $137.46 (7%) | 🛒 Add to cart |
| 90 | $2.25 | $221.24 $202.68 (8%) | 🛒 Add to cart |
| 120 | $2.12 | $294.99 $254.86 (14%) | 🛒 Add to cart |
| 180 | $2.06 | $442.49 $370.24 (16%) | 🛒 Add to cart |
| 270 | $2.00 | $663.73 $538.81 (19%) | 🛒 Add to cart |
| 360 | $1.79
Best per pill | $884.97 $646.17 (27%) | 🛒 Add to cart |
Synonyms | |||
Contrave represents one of the more interesting pharmacological approaches to weight management we’ve seen in recent years—it’s not just another appetite suppressant but rather a combination product that works on both the hunger and reward pathways in the brain. When I first reviewed the clinical trial data back in 2014, I was skeptical about combining bupropion and naltrexone, given their individual profiles, but the synergy is what makes it compelling for appropriate patients.
Key Components and Bioavailability of Contrave
The formulation contains two well-established medications: bupropion HCl extended-release (an antidepressant and smoking cessation aid) and naltrexone HCl extended-release (an opioid antagonist). The extended-release mechanism is crucial here—it maintains steady plasma concentrations, which helps minimize peak-dose side effects while providing continuous central nervous system activity. Bioavailability isn’t significantly enhanced by food, but we do recommend taking it with meals to reduce gastrointestinal discomfort, which is a common early side effect.
Mechanism of Action of Contrave: Scientific Substantiation
This is where Contrave gets interesting from a neurobiological perspective. Bupropion stimulates hypothalamic pro-opiomelanocortin (POMC) neurons, increasing melanocyte-stimulating hormone (α-MSH) release, which signals satiety. Meanwhile, naltrexone blocks opioid-mediated autoinhibition of these same POMC neurons. Essentially, they work in tandem—bupropion pushes the “brake” on hunger while naltrexone prevents the brain from overriding this signal. The combination also appears to reduce food cravings by modulating mesolimbic dopamine pathways, though the exact mechanisms here are still being elucidated.
Indications for Use: What is Contrave Effective For?
Contrave for Chronic Weight Management
The primary indication is as an adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults with initial BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity. The key here is “chronic”—this isn’t for short-term dieting but for sustained weight management.
Contrave for Reduction of Weight-Related Comorbidities
We’ve observed consistent improvements in glycemic parameters among patients with prediabetes and early type 2 diabetes, though it’s not formally indicated for diabetes treatment. Several patients have shown reduced HbA1c levels independent of weight loss, suggesting possible metabolic benefits beyond simple calorie restriction.
Instructions for Use: Dosage and Course of Administration
The titration schedule is methodical for good reason—starting slowly helps patients adapt to potential side effects. Here’s the standard escalation:
| Week | Morning Dose | Evening Dose | Total Daily Dose |
|---|---|---|---|
| 1 | 1 tablet | 0 tablets | 1 tablet |
| 2 | 1 tablet | 1 tablet | 2 tablets |
| 3 | 2 tablets | 1 tablet | 3 tablets |
| 4+ | 2 tablets | 2 tablets | 4 tablets |
The maintenance dose is two tablets twice daily (32 mg naltrexone/360 mg bupropion total daily). If patients don’t achieve at least 5% weight loss by 16 weeks, we typically discontinue—the evidence suggests unlikely benefit beyond that point.
Contraindications and Drug Interactions of Contrave
Absolute contraindications include seizure disorders, concurrent monoamine oxidase inhibitors, opioid dependence (or recent opioid use), bulimia or anorexia nervosa history, and abrupt discontinuation of alcohol or benzodiazepines. The bupropion component lowers seizure threshold, so we’re particularly cautious with patients who have history of head trauma or electrolyte imbalances.
Significant drug interactions occur with other products containing bupropion or naltrexone, MAOIs, and drugs that affect seizure threshold. The metabolic pathway (CYP2B6) interactions are less clinically significant but worth monitoring.
Clinical Studies and Evidence Base for Contrave
The COR trials (COR-I, COR-II, COR-BMOD, COR-Diabetes) form the backbone of the evidence. In COR-I, after 56 weeks, the Contrave group achieved 8.1% weight loss versus 1.8% with placebo. More importantly, 55% achieved ≥5% weight loss compared to 18% with placebo. The COR-BMOD study was particularly impressive—adding intensive behavioral therapy to Contrave resulted in 11.5% weight loss at 56 weeks.
What often gets overlooked in these large trials is the individual variation. Some patients respond dramatically within weeks, while others show minimal response despite perfect adherence. We’re still working to identify predictors of response.
Comparing Contrave with Similar Products and Choosing a Quality Product
Versus phentermine-topiramate (Qsymia), Contrave generally has better psychiatric tolerability but slower initial weight loss. Compared to liraglutide (Saxenda), it offers oral administration but typically less weight reduction. The choice often comes down to individual patient factors—I’ve found Contrave particularly useful for patients with strong food cravings or those with concomitant depression (though it’s not indicated for depression).
Quality considerations are straightforward since it’s a branded prescription product, but we do counsel patients about the importance of consistent sourcing once generics eventually become available.
Frequently Asked Questions (FAQ) about Contrave
What is the recommended course of Contrave to achieve results?
We typically evaluate initial response at 12-16 weeks. If patients haven’t lost at least 5% of body weight by then, discontinuation is recommended. Successful responders often continue for 1-2 years with periodic reassessment.
Can Contrave be combined with antidepressants?
With SSRIs, generally yes, but we monitor for serotonin syndrome symptoms (rare). With other bupropion products, absolutely not—that’s duplicative therapy and increases seizure risk.
Does Contrave cause birth defects?
Bupropion carries Pregnancy Category C designation, and adequate contraception is recommended during treatment. We discuss reproductive planning before initiation in premenopausal women.
How quickly do patients typically see weight loss with Contrave?
Most notice reduced cravings within 2-3 weeks, with measurable weight loss by 4-8 weeks. The maximal effect usually occurs around 6-9 months.
Conclusion: Validity of Contrave Use in Clinical Practice
For appropriate candidates—those committed to lifestyle changes with adequate understanding of the risk-benefit profile—Contrave offers a useful tool in the weight management arsenal. It’s not magic, but the dual mechanism does address multiple aspects of weight regulation.
I remember Sarah, a 42-year-old teacher with BMI 34 and prediabetes, who’d failed multiple dietary approaches. She described her relationship with food as “a constant negotiation.” We started Contrave, and by week 3, she reported the “food noise” had quieted significantly—she could walk past the faculty lounge snacks without the internal struggle. At 6 months, she’d lost 11% body weight and her HbA1c normalized. But it wasn’t without challenges—the initial nausea required dose adjustment, and we had a tense few weeks when her pharmacy switched to a different generic bupropion during a shortage (we switched back immediately when available).
Then there was Mark, 58, with osteoarthritis and metabolic syndrome, who discontinued after 2 months due to persistent insomnia despite all our interventions—reminding me that not every patient is a responder. Our clinic actually had heated debates about whether to even offer pharmacotherapy for weight management until we saw the 3-year follow-up data showing maintained weight loss in about 40% of continuers.
The most unexpected finding? Several patients reported reduced alcohol cravings—an off-label benefit we now watch for, though never promote. Jessica, 36, who initially sought weight management, quietly mentioned after 8 months that she’d finally stopped her evening wine routine that had concerned her for years. “I just don’t think about it anymore,” she said. These unintended positive outcomes have taught me to listen carefully beyond the weight metrics alone. At our 2-year check-in, about a third of our long-term users maintain >10% weight loss—not miraculous, but meaningful change for people who’d struggled for decades.